For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study. published in the New England Journal of Medicine,
Ania M. Jastreboff, MD, Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues performed a phase 3, double-blind trial involving 2,539 participants with obesity (1,032 of whom also had prediabetes), who were randomly assigned to receive tirzepatide at a once-weekly dose of 5, 10, or 15 mg or placebo in a 1:1:1:1 ratio. The current analysis included the participants with obesity and prediabetes who received tirezepatide or placebo for 176 weeks followed by an off-treatment period of 17 weeks.
The researchers found that the mean percentage change in body weight at 176 weeks was −12.3, −18.7, and −19.7% for those receiving 5-, 10-, and 15-mg tirzepatide doses, respectively, compared with −1.3% for those receiving placebo.
Receipt of a diagnosis of type 2 diabetes occurred in fewer participants in the tirezepatide groups versus the placebo group (1.3 versus 13.3%; hazard ratio, 0.07). After 17 weeks off treatment, 2.4 and 13.7% of those who received tirzepatide and placebo, respectively, had type 2 diabetes (hazard ratio, 0.12). Apart from COVID-19, the most common adverse events were gastrointestinal, most of which were mild-to-moderate in severity.
“Tirzepatide therapy resulted in sustained weight reduction that was accompanied by a markedly lower risk of progression to type 2 diabetes than that with placebo,” the authors write.
More information:
Ania M. Jastreboff et al, Tirzepatide for Obesity Treatment and Diabetes Prevention, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2410819
2024 Health Day. All rights reserved.
Citation: Tirzepatide yields sustained weight reduction in obesity and prediabetes, finds study (2024, November 18) retrieved 18 November 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.